Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: Digoxin Versus Beta Blocker

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-12

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ß blocker and digoxin effect on left atrium reservoir function are unknown. This is a randomized open label study to compare the effect of theses two molecules on left atrium function

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)

NCT02391337

Permanent Atrial Fibrillation

COMPLETED PHASE4

Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation

NCT00133211

Atrial Fibrillation

COMPLETED PHASE3

Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular Function

NCT02509754

Persistent Atrial Fibrillation Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction

UNKNOWN PHASE4

Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men

NCT06200311

Fibrillation, Atrial Atrial Cardiomyopathy

RECRUITING NA

Study on Left Atrial Function of Atrial Fibrillation After Radiofrequency Ablation With Statin Therapy

NCT02776956

Atrial Fibrillation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atrial fibrillation (AF) is responsible of significant morbidity and mortality. Management of signs and symptoms of heart failure generated by AF is at the center of the latest European recommendations . Mechanisms by which these symptoms are generated are very poorly understood. Heart rate control is one of the recommended strategies but remains poorly codified and generally follows the preferences and experiences of each local center. The European guidelines propose at least 4 molecules for heart rate control without emitting preferences for one molecule over the other due to the lack of robust randomized studies. Recently, a study comparing digoxin vs ß-blockers showed the superiority of digoxin in decreasing symptoms despite a comparable action on heart rate. On the other hand, the reservoir function of the left atrium (LA) has taken a central role in assessing signs of left heart failure and monitoring filling pressures . Other studies have demonstrated the association of left atrium reservoir strain with these symptoms .

It is commonly accepted that ß blockers decrease AF-related symptoms by a negative chronotropic effect thanks to their blocking action on the sympathetic system. While the action of digoxin on symptoms goes through a positive inotropic effect thanks to the increase in intracellular calcium .

However, the impact of these two molecules on the function of the left atrium has never been investigated. Our diagnostic hypothesis is that in addition to their action on heart rate, the improvement of symptoms noted by using b blockers and digoxin during the treatment of AF would go through an improvement LA reservoir function . The superiority of digoxin in the reduction of symptoms compared to ß blockers would be due to a greater improvement in reservoir function and this thanks to the increase in myocardial intracellular calcium.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Left Atrial Rhythm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Digoxin group

Patients will receive digoxin 0.25 mg once daily for a duration of 4 weeks

Group Type EXPERIMENTAL

Digoxin 0.25 mg

Intervention Type DRUG

Patients will have the dose of one tablet of 0.25mg per day

beta blocker group

Patients will receive bisoprolol 2.5 mg or 5 m twice a day for a duration of 4 weeks. The choice of dose will depend on blood pressure (BP): If systolic BP ≥ 150 mmHG, the patient will have bisoprolol 5 mg x 2 per day, If systolic BP \< 150 mmHG, the patient will have bisoprolol 2.5 mg x 2 per day

Group Type EXPERIMENTAL

Bisoprolol

Intervention Type DRUG

Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Digoxin 0.25 mg

Patients will have the dose of one tablet of 0.25mg per day

Intervention Type DRUG

Bisoprolol

Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any patient with atrial fibrillation naïve to ß-blocker and digoxin or patients followed for Atrial fibrillation and discontinued all treatment for more than a week.
* Frequency Control Strategy Decided
* Age over 18 years
* Stable hemodynamic state
* No contraindication to digoxin or ß-blocker

Exclusion Criteria

* Required rhythm control strategy
* Contraindication to one of the two
* Heart rate \<60 BPM
* Clearance rénale \<30 ml/mn
* Pregnant or breastfeeding woman
* Persistence of a resting heart rate \> 110
* Severe comorbidity with decreased life expectancy (advanced neoplasia, large stroke...)

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No